The U.S. Food and Drug Administration (FDA) approved of two treatments to treat high blood pressure (pulmonary hypertension) and cancer (multiple myeloma). United Therapeutics won approval for Tyvaso (treprostinil) Inhalation Solution, its pulmonary hypertension treatment designed for patients to improve exercise ability. Sanofi was also granted regulatory approval for Sarclisa (isatuximab) when taken in combination with dexamethasone (Kd) and carfilzomib for adults diagnosed with relapsed refractory multiple myeloma (RRMM).
Read more here.
More on: News Regulatory